glp 1 agonist clinical trials GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness Sometimes innovation comes before the

In terms of reduction in WC, 8 studies (with 232 and 189 participants from the experimental and control groups, respectively) were included for analysis

2009 6:e1000201

Deepa Sannidhi, Email: [email protected]

FDA has a more rapid approach for approval of chronic weight management drugs, permitting short phase 3 trials of 52 to 68 weeks without requiring pre-approval cardiovascular outcomes trials (CVOTs) whereas Europe insists on such trials

There are multiple amylins in phase II trials, including Amycretin (another dual amylin/GLP-1 agonist, Novo Nordisk) and Eloralintide (a single-target amylin analogue, Eli Lilly)

Therefore, GLP-1R agonists may be new and promising treatment alternatives for obese subjects